| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
| Insider | Role | Shares | Value | Buys | Sells |
|---|---|---|---|---|---|
| Date | Ticker | Insider | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|---|
Director
2 companies
Richard Aldrich last filed a Form 4 in December 2018, as Director at KALV. The filings on record cover 2 companies. Richard Aldrich's net worth is not public. Form 4 filings only show shares in the companies where this person was an insider, as of the last filing.
At the last filing, the largest reported position was 934,484 shares of KALV. Net of sales, the KALV filings show accumulation of 565,065 shares.
Richard Aldrich has 37 Form 4 filings on record from March 2015 to December 2018, across 2 companies: Director at Tempest Therapeutics (TPST), 2015–2018; Director at KalVista Pharmaceuticals (KALV), 2016–2018.
The 59 reported transactions were 25 open-market purchases, 17 stock awards, 10 gifts and 7 option or other derivative awards.
Counted by filing, the open-market trades come to 13 purchases worth about $12.3M and no sales.
The largest open-market purchase was 565,065 shares of KALV at an average $8.61 on October 12, 2017, about $4.9M.
Shares as reported in the last Form 4 for each company; the most recent is from December 2018. Values use today's prices. Any trades after the last filing were not reported, so current holdings may differ.
| Date | Ticker | Role | Type | Shares | Price | Value | Chg% | SEC |
|---|---|---|---|---|---|---|---|---|
| Oct 12, 2017 | KALV Kalvista Pharmaceuticals, Inc. | Director | Buy | 565,065 | $8.61 | $4,866,961.35 | +153.0% | |
| Jun 1, 2016 | TPST Tempest Therapeutics, Inc. | Director | Buy | 425,000 | $7.00 | $2,975,000.00 | +79.1% | |
| May 18, 2016 | TPST Tempest Therapeutics, Inc. | Director | Buy | 20,000 | $7.86 | $157,200.00 | +3.9% | |
| May 17, 2016 | TPST Tempest Therapeutics, Inc. | Director | Buy | 40,000 | $7.63 | $305,000.00 | +8.4% | |
| May 13, 2016 | TPST Tempest Therapeutics, Inc. | Director | Buy | 36,095 | $6.94 | $250,394.70 | +8.2% | |
| May 11, 2016 | TPST Tempest Therapeutics, Inc. | Director | Buy | 20,000 | $7.64 | $152,800.00 | +4.8% | |
| May 10, 2016 | TPST Tempest Therapeutics, Inc. | Director | Buy | 19,900 | $7.72 | $153,628.00 | +5.0% | |
| Mar 24, 2016 | TPST Tempest Therapeutics, Inc. | Director | Buy | 59,800 | $9.49 | $567,240.39 | +17.5% | |
| Mar 22, 2016 | TPST Tempest Therapeutics, Inc. | Director | Buy | 59,800 | $10.44 | $624,513.61 | +21.2% | |
| Mar 18, 2016 | TPST Tempest Therapeutics, Inc. | Director | Buy | 59,700 | $8.26 | $492,962.43 | +26.9% |